Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

Author:

Lawrence Nicola J., ,Chan Howard,Toner Guy,Stockler Martin R.,Martin Andrew,Yip Sonia,Wong Nicole,Yeung Annie,Mazhar Danish,Pashankar Farzana,Frazier Lindsay,McDermott Ray,Walker Roderick,Tan Hsiang,Davis Ian D.,Grimison Peter

Funder

Cancer Council Australia

Cancer Australia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Reference16 articles.

1. Howlader NNA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2014. Bethesda, https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data submission, posted to the SEER web site, April: National Cancer Institute; 2017.

2. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International germ cell Cancer collaborative group. J Clin Oncol. 1997;15(2):594–603.

3. Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S, Jacobsen EP, et al. Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecol Oncol. 2015;138(3):566–72.

4. Grimison PS, Toner GC. Management of Advanced Germ Cell Tumors: IGCCC Intermediate- and Poor-Risk Patients. In: Scardino PT, Linehan WM, Zelefsky MJ, Vogelzang NJ, Rini BI, Bochner BH, et al., editors. Comprehensive Textbook of Genitourinary Oncology. 4e ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 594–602.

5. Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862–6.

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3